FDA Approved: VOTRIENT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for VOTRIENT (pazopanib hydrochloride) from Novartis Pharmaceuticals, signaling an update to the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Soft Tissue Sarcoma

Drugs mentioned

• Votrient (Pazopanib)

Snippet

SUPPL AP for VOTRIENT (PAZOPANIB HYDROCHLORIDE)